News & Events 2007

CTI Announces the FDA allows long term use of ISA247 in Isotechnika Phase 2b Clinical Program for the Prevention of Rejection following Kidney Transplantation

October 24, 2007

CTI Clinical Trial and Consulting Services (CTI) announced that Isotechnika has received permission from the U.S. Food and Drug Administration (FDA) for the long term use of ISA247 in patients currently participating in Isotechnika’s Phase 2b kidney transplant (PROMISE) trial. Isotechnika previously announced that they had also received a “No ...

Read More

CTI Announces Complete Enrollment of the Isotechnika ISA247 Phase 2B Clinical Program for the Prevention of Rejection following Kidney Transplantation

July 5, 2007

CTI Clinical Trial and Consulting Services (CTI) announced the completion of patient enrolment in the Isotechnika Phase 2b trial assessing ISA247 for the prevention of kidney graft rejection following transplantation. Of the 332 patients enrolled, 148 patients have already completed the required six months of treatment. Isotechnika expects to have ...

Read More

CTI Announces Completes Enrollment of Phase II Trial in the US with YSPSL for Prevention of Delayed Graft Function in Renal Transplantation

May 7, 2007

Preliminary Results Presented at the 2007 American Transplant Congress CTI Clinical Trial and Consulting Services (CTI) announced the completion of patient enrollment in a Phase II clinical trial of YSPSL for prevention of delayed graft function (DGF) in kidney transplant patients. YSPSL is a recombinant molecule resulting from the ...

Read More

Join Our Mailing List